Immunogenicity of hepatitis B virus vaccine (Heptavax-B)--response of healthy adults.
We vaccinated 30 healthy adults who were susceptible to hepatitis B virus with 20 mug of Merck Sharp & Dohme vaccine at zero, one and six months and measured their antibody (anti-HBs) response weekly for four weeks and monthly for at least seven months. A month following the first dose 40% had antibodies and 90% were positive for anti-HBs a month following the second dose. The third dose raised the response rate to 93.3% but its major effect was to substantially raise the titer of virtually all of the vaccinees. Two persons had no antibody response to vaccination and four others were hyporesponders. No complications or significant side effects were observed.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D008875:Middle Aged; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D017325:Hepatitis B Vaccines; D014765:Viral Vaccines